Icon

BREO ELLIPTA (nda204275)- (0.05MG/INH;EQ 0.025MG BASE/INH,0.1MG/INH;EQ 0.025MG BASE/INH,0.2MG/INH;EQ 0.025MG BASE/INH)

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE GLAXO GRP LTD
0.05MG/INH;EQ 0.025MG BASE/INH,0.1MG/INH;EQ 0.025MG BASE/INH,0.2MG/INH;EQ 0.025MG BASE/INH
No No
2031-Apr-11 2018-May-10
None 2016-May-10
None No
BREO ELLIPTA is a combination of fluticasone furoate, an inhaled corticosteroid (ICS), and vilanterol, a long-acting beta2-adrenergic agonist (LABA), indicated for: • Long-term, once-daily, maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD). • Once-daily treatment of asthma in patients aged 18 years and older.
0 0 0
Total Other Developers 7
Drugs with Suitability No
0.05MG/INH;EQ 0.025MG BASE/INH ** ** - - -
0.1MG/INH;EQ 0.025MG BASE/INH ** ** Up - -
0.2MG/INH;EQ 0.025MG BASE/INH ** ** Up - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.